A pharmaceutical company that spun out of the University of Michigan Office of Technology Transfer in 2004 raised nearly $82 million in an initial public offering July 18.
OncoMed Pharmaceuticals, now based in Redwood City, California, is developing a series of drugs meant to combat the cancer stem cells that are responsible for driving the growth and metastasis of tumors. The company offered 4.8 million shares priced at $17 each, which was above the expected range.
To read the full, original article click on this link: Initial public offering nets U-M pharmaceutical spinoff more than $80 million
